TABLE 4.
TRECs (per 106 PBMC)
| Patient | Minimum | Time after Hi Cy (mos) | Maximum | Time after Hi Cy (mos) | Time at Exacerbation |
|---|---|---|---|---|---|
| #1 | (675) | 60 | – | 78 | |
| #2 | 387 | 56 | 877 | 46 | |
| #3 | (1240) | 30 | – | 12 | |
| #4 | 323 | 35 | 1806 | 62 | |
| #5 | 147 | 10 | 4341 | 36 | |
| #6 | 80 | 4 | 1986 | 14 | |
| #7 | (412) | (pre) | – | ||
| #8 | 206 | 17 | 5983 | 27 | 36 |
| #9 | 2146 | 8 | 38540 | 9 | 5 |
| #10 | 3896 | 6 | 15350 | 8 | 17 |
| #11 | 3413 | 11 | 13259 | 1 | 5 |
| #12 | 953 | 8 | 1968 | 6 | |
| Nl #1 | (2688) | ||||
| Nl #2 | (2691) | ||||
| Nl #3 | (6796) | ||||
| Nl #4 | (4713) |
TRECs (Thymic receptor excision circles) per 106 PBMCs (peripheral blood mononuclear cells), determined as described in Methods. All 12 patients had TRECs measured; patients #1, 3, and 7, and all four controls had only one determination, at the time indicated (parentheses). Time of exacerbation is indicated in the last column. All patients were capable of producing TRECs after Hi Cy treatment. Patients # 8, 9, 10, and 11 had clinical exacerbations at times close to their maximum TREC levels, and these TREC levels were high in patients #9, 10, and 11.